Table 2 Baseline characteristics of study patients

Demographics

 - Age, years (Mean ± SD)

62.9 ± 10.1

 - Female, n (%)

201 (88.9)

 - Menopause, n (%)

177 (78.3)

 - Body mass index, kg/m² (Mean ± SD)

23.6 ± 4.2

Rheumatic diseases

 - Rheumatoid arthritis, n (%)

152 (59.8) *

 - Systemic lupus erythematosus, n (%)

56 (22) *

 - Inflammatory myopathies, n (%)

12 (4.7) *

 - Systemic sclerosis, n (%)

12 (4.7) *

 - Vasculitis, n (%)

10 (3.9) *

 - Primary Sjogren’s syndrome, n (%)

9 (3.5) *

 - Autoinflammatory disease, n (%)

3 (1.2)

Glucocorticoid use (prednisolone dose equivalent)

 - Daily dose, mg/day (median, IQR)

2.5 (1.1, 5.0)

 - Duration, month (median, IQR)

37.0 (16.8–83.3)

 - Cumulative dose, mg (median, IQR)

5,999.2 (2,585.1–12,344.2)

Bone characteristics

Fractures

 - Major osteoporotic fractures, n (%)

32 (14.2)

 - Vertebral fractures, n (%)

29 (12.8)

 - Distal radius fractures, n (%)

2 (0.9)

 - Proximal humerus fracture, n (%)

1 (0.5)

 - Hip fractures, n (%)

2 (0.9)

T-score

 - Lumbar

-1.63 ± 1.21

 - Hip

-1.38 ± 1.02

 - Femoral neck

-1.92 ± 0.93

Osteoporosis, defined as T-score ≤ -2.5 (n, %)

 - Lumbar

60 (26.5%)

 - Total hip

34 (15.0%)

 - Femoral neck

65 (28.8%)

GC-FRAX (n = 223), mean ± SD

 - FRAX MOF, with BMD (%)

12.61 ± 9.10

 - FRAX Hip, with BMD (%)

5.40 ± 6.0

 - FRAX MOF, without BMD (%)

10.65 ± 7.15

 - FRAX Hip, without BMD (%)

4.57 ± 4.77